Acute Pancreatitis (AP) Market Insights, Epidemiology and Market Forecasts 2017-2028

DUBLIN, Oct. 18, 2019 /PRNewswire/ -- The "Acute Pancreatitis (AP) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Acute Pancreatitis (AP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AP in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Pancreatitis (AP) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Acute Pancreatitis (AP) - Disease Understanding and Treatment Algorithm

The Acute Pancreatitis (AP) market report gives the thorough understanding of the Acute Pancreatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Pancreatitis in the US, Europe, and Japan.

Acute Pancreatitis Epidemiology

The total number of diagnosed incident cases of Acute Pancreatitis (AP) in 7 MM was found to be 378,835, in the year 2017.

The Acute Pancreatitis (AP) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Acute Pancreatitis Drug Chapters

This segment of the Acute Pancreatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of supportive therapies) used for the management of AP. Intravenous fluids, analgesics, antibiotics and pancreatic enzymes which comprises the treatment pattern have been covered in the report.

Acute Pancreatitis Market Outlook

The Acute Pancreatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Acute Pancreatitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Key Topics Covered:

1. Report Introduction

2. Acute Pancreatitis Market Overview at a Glance
2.1. Global Market Size of Acute Pancreatitis in 2017
2.2. Global Market Size of Acute Pancreatitis in 2028

3. Disease Background and Overview: Acute Pancreatitis
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Acute Pancreatitis Geography Wise Incident Cases
4.2.1. 7MM Diagnosed Incidence of Acute Pancreatitis (2017-2028)
4.2.2. 7MM Diagnosed Incidence of AP by Etiology (2017-2028)
4.2.3. 7MM Diagnosed Incidence of AP by Severity (2017-2028)
4.2.4. 7MM Diagnosed Incidence of AP by Gender (2017-2028)
4.2.5. 7MM Diagnosed Incidence of Recurrent AP Cases (2017-2028)
4.3. United States
4.4. EU-5
4.4.3. Italy
4.4.4. Spain
4.4.5. France
4.4.6. United Kingdom
4.5. Japan

5. Treatment Algorithm
5.1. United States
5.2. Europe
5.3. Japan

6. Unmet Need

7. Key Emerging Therapies
7.1. Key Cross Competition
7.2. CM4620: CalciMedica
7.2.1. Regulatory Milestones
7.2.2. Clinical Development
7.2.3. Product Profile
7.2.4. Clinical Pipeline Activity
7.2.4.1. Ongoing Trials Information
7.2.4.2. Clinical Trial by Phase

8. Acute Pancreatitis Market Size
8.1. Key Findings
8.2. Total 7MM Acute Pancreatitis Market Analysis
8.2.1. Overview of Total Acute Pancreatitis Market (2017-2028)

9. 7MM Acute Pancreatitis: Country-Wise Market Analysis

10. Market Drivers

11. Market Barriers

Companies Mentioned

• CalciMedica

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xw0pj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets